- Blohmer, Jens-Uwe, Prof. Dr. , Charité Berlin, Charité-Mayo-Conference distilled 2024, Spotlight Metastatic Breast Cancer: Established and New Treatment Options, 13.4.2024
Advanced breast carcinomas can spread to almost all parts of the body, particularly frequently to the CNS. The treatment of brain metastases is often difficult and complex. However, there is a new treatment option that has significantly improved progression-free survival and the overall response rate for existing metastases in the brain in studies: the antibody conjugate trastuzumab deruxtecan (T-DXd).
There are several studies that support the favourable outcomes with T-DXd:
There is also a new treatment option for patients with HR+/HER2- breast cancer. In studies, the antibody-drug conjugate Datopotamab Deruxtecan (Dato-DXd), which is directed against trophoblast cell surface antigen-2, showed improved outcomes compared to existing chemotherapies. Patients who received this drug achieved a longer PFS and a clinically-relevant increase in ORR. The safety profile did not show any new features and patients had fewer severe side effects overall than with conventional chemotherapies.
There are new treatment options for patients with advanced breast cancer that lead to longer PFS and improved outcomes. Particularly for patients with brain metastases, new approaches are available that are associated with a good response. With Dato-DXd, a new treatment pathway is also available for metastasised hormone receptor-positive forms of breast cancer, which has achieved promising results in studies.